Login

H-Tyr-Phe-OH

CAT:
804-HY-W011258
Size:
100 mg
Price:
Ask
For price, please contact [email protected]
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
H-Tyr-Phe-OH - image 1

H-Tyr-Phe-OH

  • CAS Number: 17355-11-2
  • UNSPSC Description: H-Tyr-Phe-OH (L-Tyrosyl-L-phenylalanine) is an orally active inhibitor of Angiotensin converting enzyme (ACE), with an inhibiton rate of 48% at 50 μM. H-Tyr-Phe-OH can be used as an biomarker for differentiating benign thyroid nodules (BTN) from thyroid cancer (TC). H-Tyr-Phe-OH exhibits xanthine oxidase inhibition (uric acid lowering) activity and serves as regulator in IL-8 production in neutrophil-like cells[1][2][3][4].
  • Target Antigen: Angiotensin-converting Enzyme (ACE); Xanthine Oxidase
  • Type: Peptides
  • Related Pathways: Metabolic Enzyme/Protease
  • Applications: COVID-19-anti-virus
  • Field of Research: Cancer; Inflammation/Immunology
  • Assay Protocol: https://www.medchemexpress.com/h-tyr-phe-oh.html
  • Purity: 99.46
  • Solubility: DMSO : 5 mg/mL (ultrasonic)
  • Smiles: OC([C@H](CC1=CC=CC=C1)NC([C@@H](N)CC2=CC=C(C=C2)O)=O)=O
  • Molecular Weight: 328.368
  • References & Citations: [1]Zhu Wei, et al. Biomarker containing keratin type II cytoskeleton 1b for differentiating benign thyroid nodules and thyroid cancer: China, CN114264828A[P]. 2022-04-01.|[2]Enari Hiroyuki, et al. Angiotensin converting enzyme (ACE)-inhibiting peptides, ACE inhibitors containing the peptides, their uses, and manufacture of the peptides from shark cartilage: Japan, JP2005154326A[P]. 2005-06-16.|[3]Mao Xiangchao, et al. Method for preparing cod fish peptide with xanthine oxidase inhibitory activity: China, CN113005166A[P]. 2021-06-22.|[4]Hsueh PC, et al. Metabolomic profiling of parapneumonic effusion reveals a regulatory role of dipeptides in interleukin-8 production in neutrophil-like cells. Anal Chim Acta. 2020 Sep 1;1128:238-250.
  • Shipping Conditions: Blue Ice
  • Storage Conditions: -20°C (Powder, protect from light)
  • Clinical Information: No Development Reported